Abdelkader Ehab, Yip Kay P, Cornish Kurt Spiteri
Aberdeen Royal Infirmary, Aberdeen, UK; KKESH, Riyadh, Saudi Arabia.
Aberdeen Royal Infirmary, Aberdeen, UK; Worcester Royal Hospital, Charles Hastings Way, Worcester, UK.
Saudi J Ophthalmol. 2016 Oct-Dec;30(4):221-226. doi: 10.1016/j.sjopt.2016.10.002. Epub 2016 Oct 13.
To evaluate the outcomes of pneumatic displacement of submacular hemorrhage secondary to choroidal neovascular membrane (CNV) ( = 9) and retinal arterial macroaneurysm (RAM) ( = 3).
This is a retrospective case series study of 12 eyes from 12 patients in Aberdeen Royal Infirmary, Aberdeen, UK. The mean duration of visual loss was 10.8 ± 4.11 days. All cases received intravitreal injection of expansile gas within 24 h of presentation (C3F8 in 11 cases and SF6 in one case) and postured face down for five days. Anterior chamber paracentesis was done right after gas injection. Intravitreal anti-VEGF was injected at the same time in cases with CNV. Further anti-VEGF injections were done in CNV cases as needed afterwards. Cases were followed up for 6 months.
The submacular hemorrhage was successfully displaced from underneath the fovea in all but one case. The bleeding disappeared totally in 44% of cases and was inferiorly displaced in 56%. VA improvement at 6 months was statistically significantly higher than baseline VA. All cases but 2 (one because of subfoveal fibrosis and one because of late presentation) experienced improved VA. The mean VA improved from 1.37 ± 0.18 logMAR at baseline to 0.83 ± 0.26 logMAR at 6 months. No complication related to the procedure was reported.
Pneumatic displacement of submacular hemorrhage appears to be a safe and effective technique to treat the condition. It is an easy procedure that can be done in outpatient setting. Further studies are needed to validate our results.
评估继发于脉络膜新生血管膜(CNV)(n = 9)和视网膜动脉大动脉瘤(RAM)(n = 3)的黄斑下出血进行气体置换的效果。
这是一项对英国阿伯丁皇家医院12例患者的12只眼进行的回顾性病例系列研究。平均视力丧失持续时间为10.8 ± 4.11天。所有病例在就诊后24小时内接受玻璃体内注射膨胀性气体(11例注射C3F8,1例注射SF6),并面朝下体位保持5天。气体注射后立即进行前房穿刺。CNV病例同时注射玻璃体内抗VEGF药物。之后根据需要对CNV病例进一步注射抗VEGF药物。对病例进行6个月的随访。
除1例病例外,其余所有病例的黄斑下出血均成功从黄斑中心凹下方移位。44%的病例出血完全消失,56%的病例出血向下移位。6个月时视力(VA)改善在统计学上显著高于基线视力。除2例(1例因黄斑中心凹下纤维化,1例因就诊较晚)外,所有病例的视力均有改善。平均视力从基线时的1.37 ± 0.18 logMAR提高到6个月时的0.83 ± 0.26 logMAR。未报告与该操作相关的并发症。
黄斑下出血的气体置换似乎是一种治疗该疾病的安全有效的技术。这是一种简单的操作,可以在门诊进行。需要进一步研究来验证我们的结果。